Evaluation of the impact of large scale, community directed delivery of doxycycline for the treatment of onchocerciasis: the Anti-Wolbachia (A-WOL) trial

iverpool School of Tropical Medicine (UK)0 个研究点目标入组 682 人开始时间: 2011年8月10日最近更新: 2016年10月17日

适应症

试验速览

暂无简介。

•1. Participants of both sexes aged 19 years or above
•2. Received either 6 weeks of doxycycline MDA followed by one or two rounds of annual ivermectin MDA or one or two rounds of annual ivermectin MDA alone
•3. Willingness to participate in the study by signing the informed consent form
•1. Participants of both sexes aged 19 years or above
•2. Received either 6 weeks of doxycycline MDA followed by one or two rounds of annual ivermectin MDA or one or two rounds of annual ivermectin MDA alone
•3. Presence of a minimum of one onchocercoma detected by palpation
•4. Good general health without any clinical condition under treatment with long term medication
•5. Willingness to participate in the study by signing the informed consent form

•For stages 1 and 2:
•1. Ivermectin intake since June 2010 (date of last ivermectin MDA)
•2. Intake of antibiotics (tetracyclines or rifamycins) for longer that 2 weeks since June 2007
•3. Behavioural, cognitive or psychiatric diseases that in the opinion of the trial clinician affects the ability of the participant to understand and cooperate with the study protocol
•4. Any other condition that, in the opinion of the investigator (trial clinician), would risk the safety or rights of the participants in the trial or would render the subject unable to comply with the protocol

发起方

iverpool School of Tropical Medicine (UK)